Abstract:The immune response consists of a finely-tuned program, the activation of which must be coupled with inhibitory mechanisms whenever initiated. This ensures tight control of beneficial anti-pathogen and anti-tumor responses while preserving tissue integrity, promoting tissue repair, and safeguarding against autoimmunity. A cogent example of this binary response is in the mobilization of co-stimulatory and co-inhibitory signaling in regulating the strength and type of a T-cell response. Of particular importance is the costimulatory molecule CD28 which is countered by CTLA-4. While the role of CD28 in the immune response has been thoroughly elucidated, many aspects of CTLA-4 biology remain controversial. The expression of CD28 is largely constrained to constitutive expression in T-cells and as such, teasing out its function has been somewhat simplified by a limited and specific expression profile. The expression of CTLA-4, on the other hand, while reported predominantly in T-cells, has also been described on a diverse repertoire of cells within both lymphoid and myeloid lineages as well as on the surface of tumors. Nonetheless, the function of CTLA-4 has been mostly described within the context of T-cell biology. The focus on T-cell biology may be a direct result of the high degree of amino acid sequence homology and the co-expression pattern of CD28 and CTLA-4, which initially led to the discovery of CTLA-4 as a counter receptor to CD28 (for which a T-cell-activating role had already been described). Furthermore, observations of the outsized role of CTLA-4 in T reg -mediated immune suppression and the striking phenotype of T-cell hyperproliferation and resultant disease in CTLA-4 −/− mice contribute to an appropriate T-cell-centric focus in the study of CTLA-4. Complete elucidation of CTLA-4 biology, however, may require a more nuanced understanding of its role in a context other than that of T-cells. This makes particular sense in light of the remarkable, yet limited utility of anti-CTLA-4 antibodies in the treatment of cancers and of CTLA-4-Ig in autoimmune disorders like rheumatoid arthritis. By fully deducing the biology of CTLA-4-regulated immune homeostasis, bottlenecks that hinder the widespread applicability of CTLA-4-based immunotherapies can be resolved.

Identification of CTLA-4-Positive Cells in the Human Tonsil

Oligoclonal CD4 + CXCR5 + T cells with a cytotoxic phenotype appear in tonsils and blood

The Detection of Cytotoxic T Lymphocyte about its Activity and its Application

Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation

Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types

An atlas of cells in the human tonsil

Comprehensive analysis of CTLA-4 in the tumor immune microenvironment of 33 cancer types

Molecular and Cellular Functions of CTLA-4.

Elucidating CTLA-4's role in tumor immunity: a comprehensive overview of targeted antibody therapies and clinical developments

Characterization of human skin-derived CD1a-positive lymph cells

Single-cell transcriptomics of human gut T cells identifies cytotoxic CD4+CD8A+ T cells related to mouse CD4 cytotoxic T cells

Tissue determinants of the human T cell receptor repertoire.

Precursors of human CD4+ cytotoxic T lymphocytes identified by single-cell transcriptome analysis

Concomitant in vivo production of 19 different cytokines in human tonsils

Study on Cytomorphology and Phenotypes of Human T-activated Killer Cells

Functional characterization of human T cell hyporesponsiveness induced by CTLA4-Ig

Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?

CTLA-4 expression by B-1a B cells is essential for immune tolerance

Taming tissue-specific T cells: CTLA-4 reins in self-reactive T cells

Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy

Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients